Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF vs TDF PK in Pregnant and Postpartum Women (PrEP-PP PK)
NCT04937881Phase 3Completed
- Sponsor
- University of California, Los Angeles
- Start
- Jun 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of California, Los Angeles. Primary endpoints: Tenofovir Diphosphate Levels in Plasma and Intracellular Levels in Pregnant Women at 8 weeks and Tenofovir Diphosphate Levels in Plasma and Intracellular Levels in Postpartum Women at 8 weeks. Started Jun 2022; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04937881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04937881.